Potential future therapies: Natriuretic peptides

Coronary Artery Disease

Volumn 10, Issue 6, 1999, Pages 389-394

  Lisy, Ondrej ^a   Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Congestive heart failure; Early asymptomatic left ventricular dysfunction; Natriuretic peptides; Neutral endopeptidase

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HORMONE BLOOD LEVEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0032848514     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199909000-00007     Document Type: Review

References (58)

1. DeBold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28:89-94.
2. Nakao K, Itoh H, Saito Y, Mukoyama M, Ogawa Y. The natriuretic peptide family. Curr Opin Nephrol Hypertension 1996; 5:4-11.
3. Grantham AJ, Burnett JC Jr. Natriuretic peptides in cardiovascular disease. In Samson WK, Levin ER (editors): Contemporary endocrinology: natriuretic peptides in health and disease. Totowa, NJ: Humana Press Inc.; 1997, pp. 309-326. This report is a comprehensive recent review of the natriuretic peptides in heart failure.
4. Wong SKF, Garbers DL. Receptor guanylyl cyclases. J Clin Invest 1992; 90:299-305.
5. Burnett JC Jr, Granger JP, Opgenorth TF. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol 1984; 247:F863-F866.
6. Arjona AA, Hsu CA, Wrenn DS, Hill NS. Effects of natriuretic peptides on vascular smooth-muscle cells derived from different vascular beds. Gen Pharmac 1997; 28:387-392.
7. Yamamoto K, Burnett, JC Jr, Redfield MM. Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol 1997; 273:H2406-H2414. This paper supports the concept of a lusitropic action for BNP in the control of ventricular relaxation.
8. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 1995; 25:227-234.
9. Stevens TL, Wei CM, Aarhus LL, Heublein DM, Kinoshita M, Matsuda Y, et al. Modulation of exogenous and endogenous atrial natriuretic peptide by a receptor antagonist. Hypertension 1994; 23:613-618.
10. Zhang PL, Mackenzie HS, Troy JL, Brenner BM. Effects of natriuretic peptide receptor inhibition on remnant kidney function in rats. Kidney Int 1994; 46:414-420.
11. Supaporn T, Wennberg PW, Wei CM, Kinoshita M, Matsuda Y, Burnett JC Jr. Role for the endogenous natriuretic peptide system in the control of basal coronary vascular tone in dogs. Clin Sci 1997; 90:357-362.
12. Yokota N, Bruneau BG, Kuroski-de Bold ML, de Bold AJ. Atrial natriuretic factor significantly contributes to the mineralocorticoid escape phenomenon: evidence for a guanylate cyclase-mediated pathway. J Clin Invest 1994; 94:1938-1946.
13. Lopez MJ, Wong SK, Kishinoto I, Dubois S, Mach V, Friesen J, et al. Salt resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 1995; 378:65-68. A landmark study which established a fundamental role for the natriuretic peptide system in blood pressure control.
14. John SWM, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995; 267:679-681.
15. Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension 1990; 16:301-307.
16. Field LJ, Veress AT, Steinhelper ME, Cochrane K, Sonnenberg H. Kidney function in ANF-transgenic mice. Effect of blood volume expansion. Am J Physiol 1991; 260:R1-R5.
17. Schweitz H, Vigne P, Moinier D, Frelin C, Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the Green Mamba (Dendroaspis angusticeps). J Biol Chem 1992; 267:13928-13932.
18. Lisy O, Jougasaki M, Heublein M, Schirger JA, Chen HH, Wennberg PW, et al. A new natriuretic peptide present in canine plasma and heart [abstract]. Circulation 1998; 98 (suppl 17):3920A.
19. Schirger JA, Heublein DM, Chen HH, Lisy O, Jougasaki M, Wennberg PW, et al. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin Proc 1999; 74:126-130.
20. Burnett JC Jr, Kao PC, Hu DC, Heser D, Heublein DM, Granger J, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986; 231:1145-1147.
21. Wei C-M, Heublein DM, Perrella MA, Lerman A, Rodeheffer RJ, McGregor CGA, et al. Natriuretic peptide system in human heart failure. Circulation 1993; 88:1004-1009.
22. Lerman A, Gibbons RJ, Rodeheffer RJ, Bailey KR, McKinley LJ, Heublein DM, et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993; 341:1105-1110.
23. Yamamoto K, Burnett, JC Jr, Jougasaki M, Nishimura RA, Bailey KR, Saito Y, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28:988-994. This paper provides the rationale for BNP as a serum marker for altered myocardial function and structure.
24. Hall C, Rouleau JL, Moye L, de Champlain J, Bichet D, Klein M, et al. N-terminal proatrial natriuretic factor: an independent predictor of long-term prognosis after myocardial infarction. Circulation 1994; 89:1934-1942.
25. McDonagh TA, Morrison C, Lawrence A, Ford I, Tunstall-Pedoe H, McMurray J, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997; 35:829-833. This paper established that subjects with asymptomatic ventricular dysfunction represent half of the population with left ventricular dysfunction.
26. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of LV dysfunction. Lancet 1998; 351:9-13. A landmark study supporting BNP as a blood test for CHF.
27. McKelvie RS, Yusuf S. Large trials and meta-analysis. In: Poole-Wilson PA, Colucci WS, Massie BM, Chatterjee K, Coats AJS (editors). Heart failure. New York: Churchill Livingstone; 1997. pp. 597-615.
28. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang C, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990; 82:1724-1729.
29. Brandt RR, Wright RS, Redfield MM, Burnett JC Jr. Atrial natriuretic peptide in congestive heart failure [abstract]. J Am Coll Cardiol 1993; 22 (suppl A):86A-92A.
30. Cody RJ, Atlas SA, Laragh JH, Kubo SH, Kovit AB, Ryman K, et al. Atrial natriuretic factor in normal subjects and heart failure patients: plasma levels and renal, hormonal and hemodynamic responses to peptide infusion. J Clin Invest 1986; 78:1362-1374.
31. Margulies KB, Perrella MC, Heublein DM, Burnett JC Jr. ANF-mediated renal cyclic GMP generation in congestive heart failure. Am J Physiol 1991; 260:F562-F568.
32. Stevens TL, Rasmussen TE, Wei C-M, Kinoshita M, Matsuda Y, Burnett JC Jr. Renal role of the endogenous natriuretic peptide system in acute congestive heart failure. J Cardiac Failure 1996; 2:119-125.
33. Stevens TL, Burnett, Jr., JC, Kinoshita M, Matsuda Y, Redfield MM. A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Invest 1995; 95:1101-1108.
34. Wada A, Tsutamoto T, Matsuda Y, Kinoshita M. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation 1994; 89:2232-2240.
35. Wada A, Tsutamoto T, Maeda Y, Kanamori T, Matsuda Y, Kinoshita M. Endogenous atrial natriuretic peptide inhibits endothelin-1 secretion in dogs with severe congestive heart failure. Am J Physiol 1996; 270:H1819-H1824. This report importantly links ANP to the suppression of endothelin in CHF.
36. Zhang PL, Mackenzie HS, Totsune K, Troy JL, Brenner BM. Renal effects of high-dose natriuretic peptide receptor blockade in rats with congestive heart failure. Circ Res 1995; 77:1240-1245.
37. Hobbs RE, Miller LW, Bott-Silverman C, James KB, Rincon G, Grossbard EB. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996; 78:896-901. This paper demonstrated the vasodilatory action of BNP in human CHF.
38. Marcus LS, Hart D, Packer M, Yushak M, Medina N, Danziger RS, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind, placebo-controlled, randomized crossover trial. Circulation 1996; 94:3184-3189. This report demonstrated the cardiorenal and endocrine actions of BNP in the treatment of CHF.
39. Grantham, JA, Borgeson DD, Burnett JC Jr. BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure. Am J Physiol 1997; 272:R1077-R1083.
40. Wei C-M, Kim CH, Miller VM, Burnett JC Jr. Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J Clin Invest 1993; 92:2048-2052. This paper describes a novel chimeric peptide possessing suprabiological actions.
41. Gardner DG. Designer natriuretic peptides. J Clin Invest 1993; 92:1606-1607.
42. Margulies KB, Burnett JC Jr. Neutral endopeptidase 24.11: a modulator of natriuretic peptides. Semin Nephrol 1993; 13:71-77.
43. Graf K, Koehne P, Grafe M, Zhang M, Auch-Schwelk W, Fleck E. Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cells. Hypertension 1995; 26:230-235.
44. Dussaule J-C, Stefanski A, Bea M-L, Ronco P, Aredaillou R. Characterization of neutral endopeptidase in vascular smooth muscle cells of rabbit renal cortex. Am J Physiol 1993; 264:F45-F52.
45. Granger J. Inhibitors of ANP metabolism-potential therapeutic agents in cardiovascular disease. Circulation 1990; 82:313-315.
46. Sonnenberg H, Honrath U, Chong CK, Wilson DR. Atrial natriuretic factor inhibits sodium transport in medullary collecting duct. Am J Physiol 1986; 250:F963-F966.
47. Florkowski CM, Richards AM, Espiner EA, Yandle TG, Sybertz E, Frampton CM. Low-dose brain natriuretic peptide infusion in normal men and the influence of endopeptidase inhibition. Clin Sci 1997; 92:255-260.
48. Brandt RR, Mattingly MT, Clavell AL, Barclay PL, Burnett JC Jr. Neutral endopeptidase regulates C-type natriuretic peptide metabolism and bioactivity in vivo. Hypertension 1997; 30:184-190.
49. Lainchbury JG, Nicholls MG, Espiner EA, Ikram H, Yandle TG, Richards AM. Regional plasma levels of cardiac peptides and their response to acute neutral endopeptidase inhibition in man. Clin Sci 1998; 95:547-555.
50. Margulies KB, Barclay PL, Burnett JC Jr. The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation 1995; 91:2036-2042. This report supports a unique role for NEP inhibition in limiting sodium retention in CHF.
51. Munzel T, Kurz S, Holtz J, Busse R, Steinhauer H, Just H, et al. Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure. Circulation 1992; 86:1089-1098.
52. Elsner D, Munzel A, Kromer EP, Riegger GAJ. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol 1992; 70:494-498.
53. Margulies KB, Perrella MA, McKinley LJ, Burnett JC Jr. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest 1991; 88:1636-1642.
54. French BA. Gene therapy and cardiovascular disease. Curr Opin Cardiol 1998; 13:205-213.
55. Akhter SA, Skaer CA, Kypson AP, McDonald PH, Peppel KC, Glower DD, et al. Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc Natl Acad Sci USA 1997; 94:12100-12105.
56. Tripathy S, Goldwasser E, Lu M-M, Barr E, Leiden J. Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus. Proc Natl Acad Sci USA 1994; 91:11557-11561.
57. Luchner A, Stevens TL, Borgeson DD, Redfield M, Wei C-M, Porter JG, et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998; 43:H1684-H1689. This report importantly established the gene activation of BNP during the progression of CHF, suggesting that early heart failure is a relatively BNP- deficient state.
58. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996; 94:2285-2296.